New evidence supports safety of tenofovir-sparing ART in HBV-immune people with HIV Emerging data presented at the 2025 European AIDS Clinical Society (EACS) Congress suggest that stopping tenofovir in people with HIV who have prior hepatitis B exposure poses a very small risk of hepatitis B virus (HBV) reactivation. The findings come from the Swiss…